Data are not publicly available because our study population focuses on an extremely vulnerable population, and our data contain indirect identifiers that would potentially inadvertently identify our study subjects. In line with the Declaration of Helsinki, we are under ethical obligation to offer additional safeguards in protecting this population. Under protocol P258/09/2008, the Kenyatta National Hospital -- University of Nairobi (KNH-UON) Ethics Research Committee has imposed restriction on the access of this data citing that sharing would be deemed to increase the risks or affect the safety or welfare of study participants. Data are available upon request the Secretary at KNH-UoN Ethics and Research Committee (contact via <uonknh_erc@uonbi.ac.ke>) for researchers who meet the criteria for access to confidential data.

Introduction {#sec005}
============

The Global Burden of Disease Study 2017 ranked non-communicable diseases (NCDs) as the number one cause of mortality worldwide \[[@pone.0235606.ref001]\]. In Sub-Saharan Africa (SSA), NCDs now account for 37% of productivity losses overtaking communicable diseases and heralding an epidemiologic shift from infectious causes \[[@pone.0235606.ref002]--[@pone.0235606.ref004]\]. People Living with HIV (PLHIV) are disproportionately affected by the dual disease burden \[[@pone.0235606.ref005]\]. There is renewed focus to address NCDs among PLHIV \[[@pone.0235606.ref006], [@pone.0235606.ref007]\], yet key populations (KPs) who are an important segment of this population continue to lag behind in spite of their risky lifestyle choices.

The World Health Organization (WHO) identifies key populations as defined groups who, due to specific higher-risk behaviors, are at increased risk of HIV irrespective of the epidemic type or local context \[[@pone.0235606.ref008]\]. Often, key populations have legal and social issues related to their behavior that increase their vulnerability to HIV infection \[[@pone.0235606.ref008]\]. The Joint United Nations Programme on HIV and AIDS (UNAIDS) considers five key population groups as being particularly vulnerable to HIV infection namely: men who have sex with men (MSM), sex workers (SWs), people who inject drugs (PWIDs), transgender people and prisoners \[[@pone.0235606.ref009]\].

KPs, including those in SSA, carry a disproportionate burden of HIV; yet they have been under-represented wherever studied--particularly for HIV \[[@pone.0235606.ref010]--[@pone.0235606.ref012]\]. NCD burden of four main categories---cardiovascular diseases, diabetes mellitus, chronic respiratory diseases and cancer has been estimated in the general population living with HIV in SSA \[[@pone.0235606.ref005], [@pone.0235606.ref007], [@pone.0235606.ref013]\]. The four aforementioned categories are noted to contribute 80% of premature deaths \[[@pone.0235606.ref014]\]. Despite being excluded from many primary HIV surveillance systems, KPs account for 25% of new HIV infections in SSA \[[@pone.0235606.ref009], [@pone.0235606.ref015]\]. Further, risk factors such as harmful alcohol use, tobacco smoking and injecting drug use predispose KPs to both HIV infection and acquisition and progression of NCDs \[[@pone.0235606.ref011], [@pone.0235606.ref016]\].

Despite evidence on benefits of harm reduction among KPs, NCD-HIV care has received little attention \[[@pone.0235606.ref017]\]. In SSA countries, where KPs are recognized, NCD-HIV care packages have similarly lacked an emphasis on NCD-care \[[@pone.0235606.ref018]\]. Biomedical interventions aimed at NCD-HIV care such as cancer screening are considered as desirable rather than mandatory \[[@pone.0235606.ref019]\].

Using program data from a large key populations program in Nairobi, Kenya, this study sought to describe the NCD burden among two key population groups--female sex workers (FSWs) and MSM living with HIV enrolled in the SWOP clinics. For this paper, four main NCD categories---cardiovascular diseases, diabetes mellitus, chronic respiratory diseases and cancer recorded in the patient's clinical notes over a three-year period were evaluated.

Materials and methods {#sec006}
=====================

Study design and population {#sec007}
---------------------------

Data for this study were obtained from a medical chart review of clients enrolled in a large key populations' HIV prevention, care and treatment program in Nairobi Kenya. KPs enrolled in the Sex Workers Outreach Program (SWOP) included FSWs, and MSM. Those reached by SWOP team within Nairobi County are encouraged to enroll in the funded program that provides free, friendly, acceptable and accessible minimum package of HIV prevention and treatment services for sex workers as per the Ministry of Health guidelines \[[@pone.0235606.ref019]\]. Due to rampant stigma and discrimination in Kenya for MSM, this group started accessing available HIV prevention and treatment services within the last 10 years. Hence, they are under-represented in health care programs providing targeted, accessible, acceptable and free health care services. Medical charts of KPs living with HIV enrolled between October 2012 and September 2015 at all seven SWOP Drop-in Centers (DICEs), and on HIV treatment and care program spread across Nairobi County were included in the study. Specifically, medical charts of KPs aged 15 and above living with HIV (national antiretroviral therapy (ART) tools in Kenya classify ages ≥ 15 as adults), irrespective of ART initiation status were considered for analyses. Additional inclusion criteria included identification as either being a FSW or MSM. Criteria for exclusion in this study included being HIV-uninfected, being a PWID or transgender, missing age or age \< 15 years and enrollment into the SWOP clinics before October 2012 or after September 2015.

Study procedures and data collection {#sec008}
------------------------------------

Medical records of those living with HIV enrolled in the program over the three-year period were abstracted during October and November 2018. At each of the seven constituent SWOP clinics, four trained abstractors collected data from clinic files of all HIV-infected individuals using a standardized data abstraction tool in MS-Excel. Details of each client's clinical encounter and follow-up visit during the study period were collected. Query scripts written in structured query language (SQL) were used to extract ART care data-variables contained in the national Ministry of Health (MOH) forms. All SWOP clinics utilize the nationally approved ART electronic medical records systems that contains the national MOH ART patient care forms. Variables that fell outside the purview of the query scripts were manually extracted and double-entered into the MS-Excel abstraction tool for validation.

The team worked under the supervision of a data manager and program manager who verified abstracted data for completeness and accuracy on a daily basis to assure data quality. Data was transmitted encrypted on a daily basis and stored at a server at the central SWOP office in Nairobi. All computers used for abstraction and storage were password protected and access limited to only the data management team. Data were cleaned and subsequently imported to STATA 15 (STATA Corporation, Texas USA) for data analysis.

Statistical analyses {#sec009}
--------------------

This study's analyses included medical chart records of two key population typologies: FSWs and MSM who were HIV-infected. Descriptive statistics were used to compute means, standard deviations (SD) and 95% confidence intervals (CI) for numerical variables as well as frequencies for ordinal and categorical variables. The baseline characteristics of the study participants were compared by KP type using appropriate statistics (chi-square or fisher's exact test as necessary for categorical variables and t-tests for continuous variables). Depending on the backbone antiretroviral drug molecule---nucleoside reverse transcriptase inhibitor (NRTI) or protease inhibitor (PI), antiretroviral treatment regimens were classified as either being first line or second line. The main outcome was any NCD derived from report of cardiovascular disease, diabetes mellitus, chronic respiratory diseases or cancer at enrollment and during HIV treatment and care (study period). Prevalence of the specific NCDs and any NCDs was calculated stratified by KP typology for a range of population characteristics. Univariate and multivariable logistic regression were conducted to identify factors associated with NCD diagnoses. An automated stepwise backward logistic regression approach was used to identify independent predictors of NCDs retaining variables with a p-value of 0.2 from the univariate analysis. Age, gender, alcohol use and smoking were considered apriori as potential confounders and included in the final multivariable model. Collinearity and interaction of the variables was assessed. A sensitivity check through an analysis that included missing data confirmed the assumption that data was missing at random. Missing data were not imputed. Analyses on non-clinical measures presented were based on self-reported data.

Ethical considerations {#sec010}
----------------------

The analyses of these routine HIV treatment and care data from Nairobi County SWOP clinics was approved by the Kenyatta National Hospital, University of Nairobi Ethics Review Committee; (KNH UON ERC P258/09/2008) and as part of a nested study (KNH UON ERC P720/10/2018). Prior to accessing the required data for this study, the data manager de-identified the patients' clinical charts creating anonymity as way of maintaining confidentiality. Upon enrollment into SWOP, all patients provided informed consent to clinical data collection that allowed use of their clinic charts to inform HIV prevention, care and treatment in Kenya. Annual approvals were granted by the Kenyatta National Hospital, University of Nairobi Ethics research committee upon satisfactory review of annual study progress reports under protocol P258/09/2008. Being of a secondary nature, there was no human subject interface during the conduct of this study.

Results {#sec011}
=======

Baseline characteristics of the study population {#sec012}
------------------------------------------------

Clinical encounters from October 2012 to September 2015 were analyzed for 1,478 clients. Among these individuals, 1,392 (94.2%) were FSWs, while 86 (5.8%) were MSM. Overall, majority of medical records were obtained from two SWOP facilities: Majengo (24.8%) and SWOP City (22.4%). Majengo facility served over a quarter (26.3%) of FSWs while slightly over two thirds (67.4%) of MSM sought services at SWOP City. The rest of the five SWOP clinics constituted the slightly over a half of the medical records (52.8%). Median age of FSWs was 35.3 years (interquartile range (IQR) of 30.1--41.6) and that of MSM was 26.8 years (IQR 23.2--32.1). Close to half (46.6%) of all KPs were single, 32.8% were divorced, 14.9% married and 4.9% were widowed. The proportion of FSWs that was single was lower than that of MSM (45.0% vs 72.1% respectively) ([Table 1](#pone.0235606.t001){ref-type="table"}).

10.1371/journal.pone.0235606.t001

###### Baseline characteristics of key populations living with HIV attending SWOP clinics by typology, 2012--2015 (N = 1,478).

![](pone.0235606.t001){#pone.0235606.t001g}

  Characteristics                    Total (N = 1,478)   Key Population Typology                                                                
  ---------------------------------- ------------------- ------------------------- ------ --------- ------------------------------------------- ---------
  Age (years)                                                                                                                                   
   Mean \[SD\]                       35.8                \[8.5\]                   36.2   \[8.4\]   28.2                                        \[6.7\]
   15--25                            138                 9.3                       102    7.3       36                                          41.9
   25--34                            601                 40.7                      565    40.6      36                                          41.9
   35--44                            512                 34.6                      501    36        11                                          12.8
   45+                               224                 15.1                      221    15.9      3                                           3.5
  Facility                                                                                                                                      
   Donholm                           125                 8.5                       118    8.5       7                                           8.1
   Majengo                           367                 24.8                      367    26.3      N/A[^1^](#t001fn001){ref-type="table-fn"}   
   SWOP City                         331                 22.4                      273    19.6      58                                          67.4
   Kariobangi                        193                 13.1                      181    13        12                                          14
   Kawangware                        201                 13.6                      196    14.1      5                                           5.8
   Langata                           111                 7.5                       107    7.7       4                                           4.7
   Thika Road                        150                 10.2                      150    10.8      N/A                                         
  Marital Status                                                                                                                                
   Married                           220                 14.9                      202    14.5      18                                          20.9
   Widowed                           72                  4.9                       71     5.1       1                                           1.2
   Divorced                          484                 32.8                      479    34.4      5                                           5.8
   Single                            689                 46.6                      627    45.0      62                                          72.1
  WHO Stage at Enrolment                                                                                                                        
   I-II                              1279                86.6                      1198   86.1      81                                          94.2
   III---IV                          123                 8.3                       121    8.7       2                                           2.3
   Undocumented                      76                  5.1                       73     5.2       3                                           3.5
  CD4 T-Cell Count                                                                                                                              
   \<200                             257                 17.4                      251    18        6                                           7
   200--349                          405                 27.4                      369    26.5      36                                          41.9
   350--499                          326                 22.1                      305    21.9      21                                          24.2
   500+                              404                 27.3                      388    27.9      16                                          18.6
   Undocumented                      86                  5.8                       79     5.7       7                                           8.1
  Antiretroviral Treatment Regimen                                                                                                              
   First line (NRTI based)           1462                98.9                      1376   98.9      86                                          100.0
   Second line (PI based)            16                  1.1                       16     1.2       0                                           0

^1^N/A -Not applicable since the facility was an FSWs only clinic and did not enroll MSM during the study period.

At entry into SWOP, 97.7% of KPs in this study cohort were HIV infected. Sixteen clients across both KP typologies (11 FSWs and 5 MSM), initially HIV-uninfected at entry into SWOP, seroconverted during follow up. Seroconversion among FSWs was 0.8% while that of MSM was 5.8% (results not shown). At the time of enrollment into HIV care, most KPs (86.6%) were at an early (stage I--II) WHO clinical stage. Less than a fifth (17.4%) of all clients had a CD4 T-cell count of less than 200 cells/mm^3^. Over a quarter (27.9%) of FSWs and 18.6% of MSM had a CD4 count of 500 cells/mm^3^ and above. Nearly all (98.9%) clients enrolled were initiated on a first line antiretroviral regimen ([Table 1](#pone.0235606.t001){ref-type="table"}).

Prevalence of NCDs among key populations living with HIV {#sec013}
--------------------------------------------------------

A total of 271, 18.3% (95% CI: 16.4--20.4), KPs living with HIV had an NCD diagnosis in their clinical chart records. The vast majority, 95.2% (258 cases) of all the NCDs were from the FSWs. About a third (33.9%) of the NCDs were reported from Majengo, where 25.1% (95% CI: 20.7--29.8) of FSWs at this facility had an NCD diagnosis. A similar proportion of MSM had an NCD diagnosis in their medical charts at Kariobangi 25.0%, (95% CI: 5.5--57.2). KPs aged between 35--44 years had the highest number of NCD diagnoses 108/271, 21.1% (95% CI: 17.6--24.9) ([Table 2](#pone.0235606.t002){ref-type="table"}). FSWs' NCD prevalence rose steadily with age, 7.8% (95% CI: 3.5--14.9) among the under 25 years of age to 33.0% (95% CI: 26.9--39.7) among those aged 45 years and above. MSM NCD prevalence was highest among those aged 35--44 years, 18.2% (95% CI: 2.3--51.8) and lowest among those aged between 25 and 34 years 11.1% (95% CI: 3.1--26.1) ([Fig 1a](#pone.0235606.g001){ref-type="fig"}).

![**a.** All NCD prevalence by age and KP typology. **b.** CVD prevalence by age and KP typology. **c.** CRD prevalence by age and KP typology. **d.** Cancer prevalence by age and KP typology.](pone.0235606.g001){#pone.0235606.g001}

10.1371/journal.pone.0235606.t002

###### Prevalence of Non-Communicable Diseases (NCDs) among key populations living with HIV by selected characteristics at SWOP clinics, 2012--2015.

![](pone.0235606.t002){#pone.0235606.t002g}

  Characteristics                      Categories      *N*    Overall                FSW                   MSM                                                               
  ------------------------------------ --------------- ------ ---------------------- --------------------- ---------------------- --------------------- -------------------- --------------------
  Facility                             Donholm         125    19                     15.2 \[9.4--22.7\]    18                     15.3 \[9.3--23.0\]    1                    14.3 \[0.4--57.9\]
  Majengo                              367             92     25.1 \[20.7--29.8\]    92                    25.1 \[20.7--29.8\]    N/A                                        
  SWOP city                            331             58     17.5 \[13.6--22.1\]    49                    18.0 \[13.6--23.0\]    9                     15.5 \[7.4--27.4\]   
  Kariobangi                           193             27     14.0 \[9.4--19.7\]     24                    13.3 \[8.7--19.1\]     3                     25.0 \[5.5--57.2\]   
  Kawangware                           201             32     15.9 \[11.2--21.7\]    32                    16.3 \[11.4--22.3\]    0                     0                    
  Langata                              111             4      3.6 \[1.0--9.0\]       4                     3.74 \[1.0--9.3\]      0                     0                    
  Thika Road                           150             39     26.0 \[19.2--33.8\]    39                    26.0 \[19.2--33.8\]    N/A                                        
  Age bands (years)                    \<25            138    15                     10.9 \[6.2--17.3\]    8                      7.8 \[3.5--14.9\]     7                    19.4 \[8.2--36.0\]
  25--34                               601             75     12.5 \[9.9--15.4\]     71                    12.6 \[9.9--15.6\]     4                     11.1 \[3.1--26.1\]   
  35--44                               512             108    21.1 \[17.6--24.9\]    106                   21.2 \[17.7--25.0\]    2                     18.2 \[2.3--51.8\]   
  45+                                  224             73     33.0 \[22.5--35.8\]    73                    33.0 \[26.9--39.7\]    0                     0                    
  Body Mass Index (kg/m^2^)            \<18.5          80     8                      10.0 \[4.4--18.8\]    8                      11.3 \[5.0--21.0\]    0                    0
  18.5--24.9                           647             79     12.2 \[9.8--15.0\]     69                    11.8 \[9.3--14.7\]     10                    15.9 \[7.9--27.3\]   
  25--29.9                             420             83     19.8 \[16.1--23.9\]    80                    19.6 \[15.9--23.8\]    3                     25.0 \[5.5--57.2\]   
  30+                                  301             98     32.6 \[27.3--38.2\]    98                    32.8 \[27.5--38.4\]    0                     0                    
  Sex partner type                     Casual client   282    51                     18.1 \[13.8--23.1\]   46                     18.3 \[13.7--23.6\]   5                    16.7 \[5.6--34.7\]
  Regular client                       78              8      10.3 \[4.5--19.2\]     8                     11.4 \[5.1--21.3\]     0                     0                    
  Regular; Casual clients + Partner    620             116    18.7 \[15.7--22.0\]    114                   18.8 \[15.7--22.1\]    2                     15.4 \[1.9--45.5\]   
  Regular partner                      15              2      13.3 \[1.7--40.5\]     1                     50.0 \[1.3--98.7\]     1                     7.7 \[0.2--36.0\]    
  Undocumented                         482             94     19.5 \[16.06--23.3\]   89                    19.35 \[15.8--23.3\]   5                     22.7 \[7.8--45.4\]   
  Condom use                           No              10     1                      10 \[0.3--44.5\]      1                      25.0 \[0.6--80.6\]    0                    0
  Yes                                  1102            194    17.6 \[15.4--20.0\]    186                   17.9 \[15.6--20.3\]    8                     12.9 \[5.7--23.9\]   
  Undocumented                         365             76     20.8 \[16.8--25.4\]    71                    20.5 \[16.3--25.1\]    5                     27.9 \[9.7--53.5\]   
  Alcohol consumption (Cage per day)   0               419    70                     16.7 \[13.2--20.6\]   67                     17.1 \[13.5--21.2\]   3                    10.7 \[2.3--28.2\]
  1                                    871             162    18.6 \[16.1--21.3\]    156                   18.7 \[16.1--21.5\]    6                     15.4 \[5.9--30.5\]   
  4                                    106             18     17.0 \[10.4--25.5\]    15                    15.3 \[8.8--24.0\]     3                     37.5 \[8.5--75.5\]   
  Undocumented                         79              21     26.6 \[17.3--37.7\]    20                    29.4 \[19.0--41.7\]    1                     9.1 \[2.3--41.3\]    
  Smoking (Packs per day)              0               920    160                    17.4 \[15.0--20.0\]   147                    17.5 \[15.0--20.2\]   13                   17.1 \[9.4--27.5\]
  1                                    87              21     24.1 \[15.6--34.5\]    21                    25.0 \[16.2--35.6\]    0                     0                    
  2                                    29              2      6.9 \[0.9--22.8\]      2                     8.0 \[1.0--26.0\]      0                     0                    
  Undocumented                         444             88     19.8 \[16.2--23.8\]    88                    20.0 \[16.3--24.0\]    0                     0                    
  Drugs use                            No              1337   250                    18.7 \[16.7--20.9\]   237                    18.9 \[16.8--21.2\]   13                   16.1 \[8.8--25.9\]
  Yes                                  125             16     12.8 \[7.5--20.0\]     16                    13.2 \[7.8--20.6\]     0                     0                    
  CD 4 cells/mm^3^                     \<200           258    34                     13.2 \[9.3--18.0\]    34                     13.5 \[9.6--18.4\]    0                    0
  200--349                             404             82     20.3 \[16.4--24.5\]    76                    20.6 \[16.6--25.1\]    6                     16.7 \[6.4--32.8\]   
  350--499                             325             67     20.6 \[16.3--25.4\]    63                    20.6 \[16.3--25.6\]    4                     19.1 \[5.5--41.9\]   
  500+                                 404             84     20.8 \[16.9--25.1\]    81                    20.8 \[16.9--25.3\]    3                     18.8 \[4.1--45.6\]   
  ART Regimen                          First line      1464   268                    18.3 \[16.4--20.4\]   255                    18.5 \[16.5--20.7\]   13                   15.1 \[8.3--24.5\]
  Second line                          16              3      18.8 \[4.1--45.7\]     3                     18.8 \[4.1--45.7\]                           0                    

FSWs, female sex workers; MSM, Men who have sex with men; ART, antiretroviral therapy; N, total number of participants in each category; n, number of participants with NCD; %, percentage with NCDs

At enrollment into HIV care, 34/271, 12.5%, KPs living with HIV and with an NCD diagnosis had advanced disease with a CD4 of less than 200 cells/mm^3^. All 34, were FSWs and had an NCD prevalence of 13.5% (95% CI: 9.6--18.4). Thirty one percent of KP clients living with HIV and diagnosed with an NCD had an enrollment CD4 of ≥ 500 cells/mm^3^. For both KP typologies, NCD prevalence for the ≥ 500 cells/mm^3^ CD4 category was close to a fifth; 20.8% (95% CI; 16.9--25.3) for FSWs and 18.8% (95% CI; 4.1--45.6) for MSM respectively. Nearly all, 268/271, 98.9%, of KPs with an NCD diagnosis were currently on an NRTI-based first line ART regimen. Three FSWs were on a protease inhibitor (PI) based second line regimen and had an NCD prevalence of 18.8% (95% CI: 4.1--45.7). Two thirds, (66.8%) of KPs living with HIV and with an NCD diagnosis had a body mass index (BMI) range of either being overweight 83/271, 30.6% or obese 98/271, 36.2%. Prevalence of NCD among overweight FSWs was 19.6% (95% CI: 15.879--23.8). Overweight MSM had an NCD prevalence of 25.0% (95% CI: 5.5--57.2) ([Table 2](#pone.0235606.t002){ref-type="table"}).

Most KP clients living with HIV and an NCD diagnosis, 116/271, 42.8% reported a mixed profile of sexual partners that included both regular and casual sexual clients as well as an intimate sexual partner. Among FSWs with a mixed profile of partners, NCD prevalence was 18.8% (95% CI: 15.7--22.1). Close to two fifths (38.5%) of HIV-infected MSM with an NCD diagnosis had a casual client and an NCD prevalence of 16.7% (95% CI: 5.6--34.7). Vast majority (99.4%) of both FSWs and MSM reported consistent use of condoms with casual clients ([Table 2](#pone.0235606.t002){ref-type="table"}).

Almost two thirds, 180/271, 66.4%, of KPs living with HIV and with an NCD diagnosis consumed alcohol with 18/180, 10%, screening positive on the CAGE tool for excessive drinking. NCD prevalence among FSWs and MSM who screened positive for excessive drinking was 15.3% (95% CI: 8.8--24.0) and 37.5% (95% CI: 8.5--75.5) respectively. However, a quarter, 70/271, 25.8%, of KPs living with HIV and with an NCD diagnosis did not take alcohol. A majority of KPs living with HIV and with an NCD diagnosis, 160/271, 59.0%, did not smoke. Close to a tenth, 23/271, 8.4%, smoked tobacco cigarettes; all were FSWs. NCD prevalence for FSWs who smoked more than one pack a day was 8.0% (95% CI: 1.0--26.0). Drug use was reported among 5.9% of KPs living with HIV and with an NCD diagnosis cohort, all being FSWs. NCD prevalence among 16 FSWs who reported drug use was 13.2% (95% CI: 7.8--20.6) ([Table 2](#pone.0235606.t002){ref-type="table"}).

### Cardiovascular disease {#sec014}

Among KPs living with HIV and with a documented NCD, 249/271, 91.8%, had a form of cardiovascular disease (CVD) that included hypertension. CVD was more frequent in FSWs than MSM 17.0% (95% CI: 15.1--19.1) vs 14.0% (95% CI: 7.4--23.1) respectively. Among FSWs, CVD prevalence was lowest in the under 25 years age band 5.9% (95% CI: 2.2--12.4) and rose across age bands to 31.7% (95% CI: 25.6--38.3) in those aged 45 years and above. Among MSM, the highest CVD prevalence was in the under 25 years age band while the lowest was in the 25--34 years age band 19.4% (95% CI: 8.2--36.0) vs 11.1% (95% CI: 3.1--26.1) ([Fig 1b](#pone.0235606.g001){ref-type="fig"}).

Prevalence of hypertension as documented in reviewed KP medical records was 1.0% (95% CI: 0.6--1.7) with all cases being from FSWs. When two or more elevated blood pressure readings taken \<12 months apart were considered, prevalence of elevated blood pressure was 16.3% (95% CI: 14.4--18.3). Proxy measure of hypertension was based on the Seventh Joint National Commission on hypertension (JNC 7) definition. Elevated blood pressure readings were more common among FSWs than MSM 16.5% (95% CI: 14.5--18.6) vs 14.0 (95% CI: 7.4--23.1) respectively. While serial elevated blood pressure readings were detected in 233/249 KP medical records, only 15/249 had a documented diagnosis of hypertension. Other CVD diagnoses such as atherosclerotic heart disease and congestive heart failure were made in 5/249 cases of CVD with a prevalence of 0.3% (95% CI: 0.1--0.8) ([Table 3](#pone.0235606.t003){ref-type="table"}).

10.1371/journal.pone.0235606.t003

###### Prevalence of Non-Communicable Diseases (NCDs) among key populations living with HIV at SWOP clinics in Nairobi, Kenya, 2012--15.
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  *NCD type*                                                       *Total (N = 1478)*   *FSW (n = 1392)*      *MSM (n = 86)*                                
  ---------------------------------------------------------------- -------------------- --------------------- ---------------- --------------------- ------ --------------------
  Any                                                              *271*                18.3\[16.4--20.4\]    *258*            18.5 \[16.5--20.7\]   *13*   15.1\[8.3--24.5\]
  Cardiovascular Disease (CVD)                                     249                  16.9 \[15.0--18.9\]   237              17.0 \[15.1--19.1\]   12     14.0 \[7.4--23.1\]
   Elevated Blood Pressure[^1^](#t003fn001){ref-type="table-fn"}   233                  16.3 \[14.4--18.3\]   221              16.5 \[14.5--18.6\]   12     14.0 \[7.4--23.1\]
    Hypertension Diagnosis[^2^](#t003fn002){ref-type="table-fn"}   15                   1.0 \[0.6--1.7\]      15               1.1 \[0.6--1.8\]      0      0
  Other CVD Diagnoses                                              5                    0.3 \[0.1--0.8\]      5                0.4 \[0.1--0.8\]      0      0
  Chronic Respiratory Disease                                      16                   1.1\[0.6--1.8\]       16               1.2 \[0.7--1.9\]      0      0
  Cancer                                                           10                   0.7 \[0.3--1.2\]      9                0.7 \[0.3--1.2\]      1      1.2 \[0.0--6.3\]

^1^Elevated blood pressure is calculated based on two elevated blood pressure readings taken \<12 months apart in line with JNC 7 definition;

^2^Hypertension diagnosis denotes documented hypertension diagnosis found in medical charts;

^3^ Diabetes mellitus is not shown on the table since no record of the condition was found in the entire study population

### Chronic respiratory disease {#sec015}

A total of 16/271 medical records of KPs living with HIV reviewed were found to have a documented chronic respiratory disease (CRD). Overall prevalence of CRD was 1.1% (95% CI: 0.6--1.8). All cases reviewed were documented cases of asthma among FSWs ([Table 3](#pone.0235606.t003){ref-type="table"}). The highest CRD prevalence was observed among FSWs aged 25--34 years 1.4% (95% CI: 0.6--2.8) ([Fig 1c](#pone.0235606.g001){ref-type="fig"}).

### Cancer {#sec016}

A total of 10/271 records of KPs living with HIV were found to have documentation of a cancer diagnosis. Overall prevalence of cancer was estimated at 0.7% (95% CI: 0.3--1.2). Nine of the ten cancer diagnoses were of cervical cancer among FSWs. Cervical cancer diagnoses were made at two SWOP facilities--Donholm and Kawangware. The type of cancer was not specified for the one cancer diagnosis made on an MSM. Although 8 of the 10 cancer cases reported a mixed profile (regular clients, casual clients and a regular partner) for their sexual partner, all were found to have consistent condom use (results not shown). Majority of cervical cancer diagnoses (5/9) were made among the 25--34 years age-band. The one MSM who had a cancer diagnosis was in the 35--44 years age band ([Fig 1d](#pone.0235606.g001){ref-type="fig"}).

### Diabetes mellitus {#sec017}

In this cohort of KP clients living with HIV, none of the FSWs or MSM were found to have a documented diagnosis of diabetes mellitus in their medical records.

Predictors of NCD among key populations living with HIV at SWOP {#sec018}
---------------------------------------------------------------

On univariate analysis, increased age among KPs living with HIV was associated with an NCD diagnosis. The unadjusted odds ratio (OR) for 35--44 years age band was 2.19 (95% CI: 1.23--3.90) (p = 0.008) and that of 45 years and above 3.96 (2.17--7.26) (p = 0.001). Increased body mass index (BMI) was associated with an NCD diagnosis among KPs living with HIV. A BMI of 25--29.9 kg/m^2^ (overweight) among the HIV- infected KP was associated with an OR 2.22 (95% CI: 1.03--4.78) (p = 0.042) while those with a BMI of ≥ 30 (obese) had an OR 4.34 (95% CI: 2.01--9.38) (p = 0.001). Similarly, increasing CD4 cells/mm^3^ was associated with a documented NCD diagnosis. Odds among CD4 counts of 200--349 cells/mm^3^ was OR 1.67 (95% CI: 1.08--2.57) (p = 0.022). CD4 counts of ≥500 cells/mm^3^ had an OR 1.72 (1.11--2.66) (p = 0.014) ([Table 4](#pone.0235606.t004){ref-type="table"}).

10.1371/journal.pone.0235606.t004

###### Risk factors for NCDs among key populations living with HIV at SWOP Clinics in Nairobi, Kenya, 2012--15.

![](pone.0235606.t004){#pone.0235606.t004g}

  Characteristics                           Categories      N      Any NCD               Unadjusted Odds Ratio   Adjusted Odds Ratio                                     
  ----------------------------------------- --------------- ------ --------------------- ----------------------- --------------------- --------------------- ----------- --
  Age in years                              15--25          138    15                    10.9 \[6.2--17.3\]      Reference                                   Reference   
  25--34                                    601             75     12.5 \[9.9--15.4\]    1.17 \[0.65--2.11\]     0.602                 0.87 \[0.45--1.67\]   0.672       
  35--44                                    512             108    21.1 \[17.6--24.9\]   2.19 \[1.23--3.90\]     0.008                 1.53 \[0.79--2.95\]   0.209       
  45+                                       224             73     32.6 \[26.5--39.2\]   3.96 \[2.17--7.26\]     0.001                 2.10 \[0.98--4.49\]   0.055       
  Sex                                       Female          1392   258                   18.5 \[16.5--20.7\]     Reference                                   Reference   
  Male                                      86              13     15.1\[8.3--24.5\]     0.78 \[0.43--1.43\]     0.428                 1.39 \[0.69--2.79\]   0.354       
  Smoking                                   No              918    160                   17.4 \[15.0--20.0\]     Reference                                   Reference   
  Yes                                       116             23     19.8 \[13.0--28.3\]   1.17 \[0.72--1.91\]     0.524                 1.17 \[0.67--2.04\]   0.583       
  Alcohol Use                               No              420    70                    16.7 \[13.2--20.6\]     Reference                                   Reference   
  Yes                                       979             180    18.4 \[16.0--21.0\]   1.13 \[0.83--1.53\]     0.442                 0.95 \[0.66--1.38\]   0.794       
  Drug Use                                  No              1336   250                   18.7 \[16.7--20.9\]     Reference                                   Reference   
  Yes                                       125             16     12.8 \[7.5--20.0\]    0.64 \[0.37--1.10\]     0.104                 1.25 \[0.66--2.39\]   0.5         
  Body Mass Index (kg/m^2^)                 \<18.5          80     8                     10.0 \[4.4--18.8\]      Reference                                   Reference   
  18.5--24.9                                647             79     12.2 \[9.8--15.0\]    1.25 \[0.58--2.70\]     0.566                 1.21 \[0.49--3.00\]   0.680       
  25--29.9                                  420             83     19.8 \[16.1--23.9\]   2.22 \[1.03--4.78\]     0.042                 1.73 \[0.69--4.39\]   0.246       
  30+                                       301             98     32.6 \[27.3--38.2\]   4.34 \[2.01--9.38\]     0.001                 2.87 \[1.11--7.41\]   0.029       
  ART Regimen                               NRTI based      1462   268                   18.3 \[16.4--20.4\]     Reference                                   N/A         
  PI based                                  16              3      18.8 \[4.1--45.6\]    1.03 \[0.29--3.63\]     0.966                                                   
  CD4                                       \<200           257    34                    13.2 \[9.3--18.0\]      Reference                                   Reference   
  200--349                                  405             82     20.3 \[16.4--24.5\]   1.67 \[1.08--2.57\]     0.022                 1.42 \[0.86--2.35\]   0.171       
  350--499                                  326             67     20.6 \[16.3--25.4\]   1.70 \[1.08--2.66\]     0.021                 1.25 \[0.72--2.16\]   0.431       
  500+                                      404             84     20.8 \[16.9--25.1\]   1.72 \[1.11--2.66\]     0.014                 1.08 \[0.63--1.86\]   0.780       
  Previous TB history                       No              1471   269                   18.3 \[16.3--20.4\]     Reference                                   N/A         
  Yes                                       6               1      16.7 \[0.4--64.1\]    0.89 \[0.10--7.68\]     0.918                                                   
  Sex Partner Type                          Casual client   282    51                    18.1 \[13.8--23.1\]     Reference                                   N/A         
  Regular client                            78              8      10.3 \[4.5--19.2\]    0.51 \[0.23--1.14\]     0.103                                                   
  Regular client + Partner +Casual Client   621             116    18.7 \[15.7--22.0\]   1.04 \[0.72--1.50\]     0.831                                                   
  Regular Partner                           15              2      13.3 \[1.7--40.5\]    0.70 \[0.15--3.18\]     0.641                                                   

NCD: Non-communicable diseases. CI: Confidence interval.

Other predictive variables considered in the univariate analyses (sex, smoking, alcohol use, drug use, current ART regimen, sexual partner profile, and previous history of TB) were all not significant at a p-value of 0.2. Even though increased age, BMI and CD4 were associated with NCD diagnosis in unadjusted analyses, significant association with NCD diagnosis in the adjusted analyses remained only for categories of ≥ BMI 30 kg/m^2^, and ages ≥ 45 years (borderline statistically significant) ([Table 4](#pone.0235606.t004){ref-type="table"}).

Discussion {#sec019}
==========

This study described the burden of NCDs among key populations (KPs) living with HIV enrolled at a large prevention and treatment program in Nairobi, Kenya. It determined prevalence of four NCD conditions: cardiovascular diseases, diabetes mellitus, chronic respiratory illnesses and any form of cancer among two KP typologies--FSWs and MSM living with HIV at seven SWOP clinics in Nairobi. Further, distribution of prominent NCD risk factors and associated correlates among the two KP typologies were explored. This study comes against a backdrop of a rising NCD epidemic in SSA among PLHIV in the context of an evolving HIV epidemic with high unmet response for KPs \[[@pone.0235606.ref020], [@pone.0235606.ref021]\]. A high overall prevalence of any of the four NCDs (18.3%) was found among both HIV-infected FSWs and MSM. Despite a heightened impetus to refocus on populations at increased risk for both NCDs and HIV infection, studies among key populations living with HIV remain rare \[[@pone.0235606.ref022]\]. That notwithstanding, systematic reviews outside SSA suggest that sexual minorities exhibit higher rates of NCDs \[[@pone.0235606.ref011]\]. Contrastingly, study findings from SSA point to comparably lower prevalence rates of NCDs (4.7%, 11.5% and 21.2%) among general population PLHIV clients \[[@pone.0235606.ref005], [@pone.0235606.ref013], [@pone.0235606.ref023], [@pone.0235606.ref024]\].

Study findings from concentrated HIV epidemics that are driven by an increased prevalence of HIV among key populations, point to high prevalence of NCDs among PLHIV \[[@pone.0235606.ref025]\]. In a Cambodian study among PLHIV, close to half (47.8%) of total study participants had one or more NCDs with 75% unaware of their disease condition prior to the study \[[@pone.0235606.ref026]\]. A recent modeling report from Kenya estimated 33% of HIV negative individuals and 36% of PLHIV to have at least one NCD. Further, prevalence of hypertension among HIV negative individuals was projected to grow from 19.9% in 2018 to 23% in 2035. This was in stark comparison to a growth from 29.9% to 37.4% among PLHIV over a similar period \[[@pone.0235606.ref027]\]. These findings enunciate the excess NCDs burden among key populations and point to the need for routine active screening to increase early identification.

Evidence around cardiometabolic risk factors for NCDs among PLHIV is mixed. While some studies suggest that HIV infection is associated with lower BMI, triglycerides and blood pressure readings \[[@pone.0235606.ref028], [@pone.0235606.ref029]\], several others point to an increased prevalence of hypertension and obesity \[[@pone.0235606.ref005], [@pone.0235606.ref007], [@pone.0235606.ref030]\]. There are mixed associations with ART use on the prevalence of NCDs with some studies suggesting no associations with hypertension \[[@pone.0235606.ref023], [@pone.0235606.ref031]\] while others finding an increased odds for hypertension, dyslipidemia and other cardiovascular conditions \[[@pone.0235606.ref029], [@pone.0235606.ref030], [@pone.0235606.ref032]\]. Although chronic immune activation contributes to increased hypertension among PLHIV, the inflammatory milieu is poorly understood \[[@pone.0235606.ref033]\]. ART associated endothelial dysfunction \[[@pone.0235606.ref034]\], increasing age and longevity on ART treatment have also been associated with increased prevalence of NCDs among PLHIV \[[@pone.0235606.ref023], [@pone.0235606.ref030], [@pone.0235606.ref032]\]. In this study, close to two thirds of KPs living with HIV who had an NCD diagnosis, were either obese or overweight. A majority were FSWs. A higher prevalence of NCD diagnoses was observed with increased age.

This study found 1.0% prevalence of hypertension from clinical records. Using this study's proxy for hypertension of two or more blood pressure readings taken less than 12 months apart, the prevalence of hypertension rose to 16.3%. Further, this study found a low prevalence of other CVD diagnoses (0.3%). Similar discrepancies have been reported in other studies in SSA \[[@pone.0235606.ref013], [@pone.0235606.ref035]\]. In a South African study, prevalence of hypertension was higher during the day of the interview than when compared to both self-report and client records \[[@pone.0235606.ref035]\]. While the underdiagnosis in this latter study may be attributed to 'white coat hypertension', this study was considered as having a much more robust estimate of hypertension prevalence. However, while other studies reported high prevalence of other CVD diagnoses, isolating confounders of central nervous system (CNS) infections especially among ART naïve immunosuppressed clients proved difficult \[[@pone.0235606.ref036]\]. In this study, low prevalence of other CVD diagnoses, chronic respiratory diseases (1.1%), and diabetes mellitus (no cases) could have been attributed to absence of routine screening against a backdrop of a non-integrated NCD and HIV care system \[[@pone.0235606.ref037], [@pone.0235606.ref038]\].

ART treatment for KPs has generally followed a similar trajectory to that of the general population. \[[@pone.0235606.ref008]\]. Expanded ART eligibility over recent years has seen KPs with higher CD4 levels initiating ART through the Test and Treat platform. In this study, less than a fifth of KPs had advanced disease (less than CD4 count of 200 cells/mm^3^) demonstrating benefits of the adopted test and treat strategy. A significant association between an NCD diagnosis and CD4 measurement was not found. While this is similar to findings in SSA \[[@pone.0235606.ref035]\], studies in high income countries have found associations between NCDs and a detectable viral load \[[@pone.0235606.ref039]\]. The underdiagnoses of NCDs that was common in this study, may have contributed to the absence of an association between NCD diagnosis and CD4 measurements.

Key populations engage in risky behavior that increase their risk for NCDs. Studies have documented harmful consumption of alcohol, smoking tobacco, illicit drug use, and risky sexual behaviors among KPs as factors that increase their risk for NCDs \[[@pone.0235606.ref040]--[@pone.0235606.ref042]\]. A systematic review among KPs in SSA, found a median prevalence of alcohol misuse based on AUDIT/CAGE of 32.8%; and that of illicit drug use ranging from 0.1% to 97.1% for injecting drug users \[[@pone.0235606.ref016]\]. Difficult social conditions, including criminalization of sex work, uneven coverage of biomedical interventions and stigma impact negatively on NCDs among KPs \[[@pone.0235606.ref011], [@pone.0235606.ref020], [@pone.0235606.ref021]\]. In this study, a high prevalence of NCDs (18.7%) was observed among FSWs who screened positive for excessive drinking. Among MSM, the prevalence was close to 2.5 times as high, albeit drawn from a small sample size. A tenth of the KPs smoked and had an NCD prevalence of less than 10%. Illicit drug use was reported by about one in twenty KPs, who also reported a low NCD prevalence. Close to a half of all KPs living with HIV who had an NCD diagnosis reported a mixed profile of sexual partners but with near universal condom use. Although sex work remains criminalized in this study setting, KPs receiving care at SWOP had good access to biomedical interventions including prevention and treatment services at both fixed clinics and through peer outreach models.

A recent systematic review on the Global burden of disease indicates that cancer cases have increased in developing countries of SSA and contribute significantly to years of life lost to disability \[[@pone.0235606.ref043]\]. Utilizing registry data from Malawi, an earlier study pointed to a high burden of AIDS defining cancers -predominantly Kaposi sarcoma and cervical cancer that were associated with late initiation of ART---WHO stage III and IV \[[@pone.0235606.ref044]\]. In this study, a low prevalence of cancer (0.7%) was found with cervical cancer as the predominant cancer type. The low prevalence of cancer could have been attributed to early initiation and test and treat ART policies. In this study only 13.2% of KPs had a CD4 of \<200 cells/mm^3^ at initiation of ART further explaining the low prevalence of AIDS-defining malignancies including Kaposi sarcoma. Additionally, introduction of cervical cancer screening towards the end of the study period in early 2015 could serve to explain the low number of cancer cases. Studies among HIV-infected FSWs in similar settings have found human papilloma virus (HPV) 51 and 52 showing independent associations with abnormal cervical cytology among FSWs \[[@pone.0235606.ref045]\]. Studies among MSM elsewhere found high rates of HPV type 16 infection that was associated with anal intraepithelial neoplasia (AIN) and anal cancer \[[@pone.0235606.ref046]\]. Records of cases in this study lacked both staging details and any associations with HPV serotypes thus limiting ability to further characterize the cancer burden.

This study represents some of the earliest attempts at quantifying NCD burden among KPs living with HIV in the SSA setting. However, this study was not without limitations. The cross-sectional nature of this study design limited inferences that could be adduced. While several studies, particularly from general population PLHIV demonstrate increased incident NCD cases \[[@pone.0235606.ref023], [@pone.0235606.ref030]\], this study's design limited the description of incidence, and outcomes following ART treatment.

Although this paper highlights the prevalence of key NCDs in a group of FSWs and MSM enrolled in a funded HIV prevention and treatment program in Nairobi Kenya, majority of those with conditions of interests were women. Similar to many other countries in SSA, sex work and same sex relationships in Kenya are not only generally criminalized but also highly stigmatized \[[@pone.0235606.ref020]\]. Females who sell sex however seem to be more tolerated than MSM engaged in the trade. The latter suffer double stigma and their position is further worsened by being HIV infected. Therefore, females were over represented in the study sample as fewer men out of the many closeted MSM have taken that leap of faith to enroll in ongoing HIV prevention and treatment programs. The over representation of women in this study's sample limits generalizability of study results to key populations experiences in Kenya or the region. That notwithstanding, this study provides important insights into NCD burden in this marginalized population that has not been reported elsewhere.

Several studies indicate high levels of discrimination and uneven access for KP to HIV/NCD and SRH services \[[@pone.0235606.ref047]--[@pone.0235606.ref049]\]. However, being in an urban set-up and operating KP only services, with linkages to legal support systems, KPs in this study were considered emancipated with improved access to HIV care. The absence of routine glucose monitoring at SWOP clinics could have contributed to the absence of any reported cases of diabetes. Similarly, detection of hypertension based on updated guidelines that require a 24-hour mean blood pressure reading was limited owing to operational challenges at SWOP clinics \[[@pone.0235606.ref050]\].

Conclusion {#sec020}
----------

This study found a high prevalence of NCDs among KPs living with HIV on ART at a large prevention and treatment program in Nairobi Kenya. This study's results call for an urgent shift in refocusing HIV and NCD prevention in key populations targeted by ongoing programs in the face of a changing HIV epidemic. With integrated HIV/NCD care models being considered to address the growing syndemic for general population PLHIV, KPs will require similar strategies. Efforts to operationalize HIV/NCD integration through strengthening workforce strategies and revision and simplification of HIV tools to include NCD screening are an urgent priority. Differentiated approaches to delivering KP services and overcoming of regulatory barriers to legitimize lay and peer approaches as part of healthcare system warrant consideration. Strengthening data collection and surveillance of NCDs among both general population and KP PLHIV are necessary to inform effective HIV/NCD integration prevention and treatment models and policies.

We acknowledge all clients at all seven SWOP clinics, whose data was used in the preparation of this manuscript. Further, we acknowledge the University of Manitoba Research Group study team, who were instrumental in data collection activities. A sincere appreciation for all your support.
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2\. among the limitations in the discussion section, maybe you could add something about the fact that it was not possible to diagnose hypertension according to international recommendations (3 measurements at the same time, etc\...). It is clear that it was not possibile, but it would

3\. I would suggest to add some other interesting papers to the references list, as:

a\. Ibrahim MM, Damasceno A. Hypertension in developing countries. The Lancet. 2012;380(9841):611-9.

b\. Mbanya JC, Squire S, Cazap E, Puska P. Mobilising the world for chronic NCDs. The Lancet. 2011;377(9765):536-7.

c\. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, et al. Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. PLOS ONE. 2011;6(7):e22288.

d\. Ciccacci F, Tolno VT, Doro Altan A, Liotta G, Orlando S, Mancinelli S, et al. Non communicable diseases burden and risk factors in a cohort of HIV+ elderly patients in Malawi. AIDS Res Hum Retroviruses. 2019.

With this minor revision, I think the paper is valuable to be published, as provides new results for a particular group of patients that should receive more attention by the public health programs, also from and NCDs point of view.

Reviewer \#3: This is great piece of work given the attention that HIV/NCD comorbidity is receiving currently especially in countries with high HIV burden undergoing rapid epidemiological transition. The manuscript presents a clear and transparent research process with results emanating from appropriate analyses.However, the author is advised to consider making the following changes to improve manuscript readability and technical soundness.

Comment 1: Table headings ought to be in uniform format. Table 1 and Table 2 headings appear to have inconsistent formats.

comment 2: Table 2 column N should be described either by a footnote or by column heading to avoid confusing the reader with another N=271. Table 3 footnotes should be numbered consecutively:1,2,3 and not 2,2,3.

Comment 3:Could you please make the last columns for Table 2 wider in order to cover confidence intervals in one line other than two lines as is the case now?This would help your Table 2 look tidier.

Comment 4:The sentence in line 53 could read better if you removed \"albeit\" and replaced \"comparable\" with \"comparably\".

Comment 5:Please interpret statistically significant odds ratios in univariate analyses.Also in line number 35,\"unadjusted model\" should be changed to unadjusted analyses or univariate analyses since this is not one model perse, all variables assessed in univariate analyses represent individual univariate logistic models.

Comment 6: A sentence in line 37 reads \"When the model was adjusted, all prior significant associations between NCD diagnosis and increased age, unemployment status, BMI and CD4 ceased\"

Consider changing this sentence to \"even though increased age, unemployment status, BMI and CD4 were associated with NCD diagnosis in unadjusted analyses, they were not significantly associated with NCD diagnosis in the multivariate,adjusted analyses\".The authors should also explain why variables with P\> 0.2 such as sex, alcohol use and smoking were included in the multivariate model as this is not consistent with their analysis plan in which an automated stepwise backward logistic regression approach was selected to build a multivariate model to determine predictors for NCD prevalence from

independent predictors of NCDs with a p-value of 0.2 or less in univariate

analyses.

Comment 7: The author should consider adding references to his claim in line number 89 \"Studies have

90 documented harmful consumption of alcohol, smoking tobacco, illicit drug use, and risky sexual behaviors

91 among KPs as factors that increase their risk for NCDs.\"

Comment 8: The author tries to contradict ealier research findings that they did not find an association between ART use and NCD prevalence in line number 66. This should be avoided as the study was not designed to show association between ART use and NCD prevalence since the study enrolled no participants without exposure to ART .On the same note,the author also reports lack of association between NCD and detected viral load.In this study, at no point were viral load measurements reported. Therefore such claims are not supported and should be removed from the manuscript.

Comment 8: The author should remove any references in the conclusion section of the manuscript.

Reviewer \#4: The empirical analysis is competent, and the authors reference much of the relevant literature. A review on NCDs among key populations (KPs) is generally valuable, in light of concerns on the burden of NCDs among PLWH in general and specifically of the role and specific needs of key populations.

My reservations on publication of the paper in its present form primarily regard two aspects:

First, does the paper provide an analysis on NCDs among KPS? Not really. 94 percent of the sample are FSWs, and only 6 percent (n=86) MSMs. 86 percent of the cases of NCDs (total NCDs: n=271) are instances of high blood pressure (n=233), and the number instances of chronic respiratory disease (n=16) or cancers (n=10) do not allow a substantial empirical analysis. Against these numbers, is puzzling why much of the paper is cast in terms of \"NCDs\" among KPs -- it really is about high blood pressure among FSWs, and -- because implications and determinants of NCDs arguably differ -- focusing the empirical analysis on instances of any NCD blurs the lessons which could be learned.

Second, are there any useful findings? Note sure -- the results broadly mirror the empirical evidence on risk factors for hypertension -- prevalence is increasing with age and with BMI. Other factors appear irrelevant (this could be tested more explicitly -- do factors pervasive with respect to key populations play any role?). However, we would also want to understand whether prevalence of NCDs differs from prevalence in the general population. Doing such a comparison explicitly is beyond the scope of this paper (sample on KPs only), but the authors do not exhaust possibilities on comparing their findings with data on the general population (e.g., from DHS and related data). Relatedly, what is the relevance of the findings with regard to the management of HIV or NCDs among key populations?

Minor points:

It is not clear on what basis variables have been excluded in the multivariate analysis (Table 4). Excluding ART regimen and prior TB history appears sensible (p-value\>0.9 in univariate regression), but there are numerous other variables with p-values in the vicinity or 0.7 or 0.8 in the multivariate analysis which are included in the regression.

Table 4: Review p-value of 1.11, BMI 30+ adjusted odds ratio.

In a couple of places, I felt that the paper would benefit from a round of copy-editing to improve precision.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Pheak CHHOUN

Reviewer \#2: No

Reviewer \#3: Yes: Blessings Gausi, MD MPH.

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235606.r002

Author response to Decision Letter 0

24 Apr 2020

Reviewer \#1:

This paper shows an interesting topic and information on NCD among key population living with HIV in Kenya. It shows a relatively high prevalence of NCDs in this population. The data is valuable but some aspects of the analysis and presentation of results are very unclear to me at present and require substantial improvement. I am also not convinced yet why the data cannot be share for publication with the reason explained.

Response: We wish to thank the reviewer for this comment. We wish to confirm to the reviewer that we have made every effort to make our analysis and presentation of the data as transparent as possible. Following PLOS's data privacy policy and declaration of Helsinki on protecting vulnerable populations, we are under ethical obligation to safeguard the identity of our study participants. Further, in Kenya, key populations are in conflict with the law, and efforts to recognize them have been vehemently thwarted. Under protocol P258/09/2008, the Kenyatta National Hospital -- University of Nairobi (KNH-UON) Ethics Research Committee has imposed restriction on the access of this data citing that sharing would be deemed to increase the risks or affect the safety or welfare of study participants. However, we wish to confirm that data access can be granted upon request to the Secretary at KNH-UoN Ethics and Research Committee (<uonknh_erc@uonbi.ac.ke>) for researchers who meet the criteria for access to confidential data.

Overall comments:

Reviewer Comment 1- You may read the submission guideline of Plos One and adjust your manuscript organization as suggested such as page and line number, abbreviation used in abstract, and then resubmit it

Response: We thank the reviewer for making this observation. In our resubmission, we have carefully followed PLOS One's submission guidelines to reformat the manuscript, addressing its organization, page and line numbers. We have also spelled out abbreviation used in the abstract at the first instance that they are used.

Reviewer Comment 2- I feel hard to give the specific comment because the manuscript misses the line number in page 1 to page 13

Response: We have since reformatted the resubmitted manuscript and now have line numbers for pages 1 to 13.

Specific comments:

Reviewer Comment 1- I think the title of the paper is interesting. However, you may consider making it simpler and easier to catch up.

Response: We take note of the reviewer's suggestion. Our updated title now reads "High prevalence of noncommunicable diseases among Key populations enrolled at a large HIV prevention and treatment program in Kenya".

Reviewer Comment 2- In your abstract you may consider to used less abbreviation as suggested by the submission guideline of Plos One

Response: As per the reviewer's comment and Plos One submission guideline, we have reduced the number of abbreviations in the abstract. Additionally, we have spelled out each abbreviation at the first instance it is used.

Reviewer Comment 3- You used the team \"HIV-infected Key Populations\" in some lines it make reader confused. You may use the other term such as key population living with HIV or HIV positive key populations.

Response: We apologize for any confusion that may have arisen as a result of using the term "HIV-infected Key populations". We have since updated the manuscript using the term "key populations living with HIV".

Reviewer \#2:

Minor revisions to be made:

Reviewer Comment 1. The abstract could be divided in sections to make it easier to read

Response: We have since divided the abstract into sections improving its readability.

Reviewer Comment 2. Among the limitations in the discussion section, maybe you could add something about the fact that it was not possible to diagnose hypertension according to international recommendations (3 measurements at the same time, etc\...).

Response: We thank the reviewer for this suggestion. We have included a sentence and a reference to reflect this limitation. The sentence (lines 358-359) reads "Similarly, our detection of hypertension based on updated guidelines that require a 24-hour mean blood pressure reading was limited owing to operational challenges at SWOP clinics ."

3\. I would suggest to add some other interesting papers to the references list, as:

a\. Ibrahim MM, Damasceno A. Hypertension in developing countries. The Lancet. 2012;380(9841):611-9.

b\. Mbanya JC, Squire S, Cazap E, Puska P. Mobilising the world for chronic NCDs. The Lancet. 2011;377(9765):536-7.

c\. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, et al. Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. PLOS ONE. 2011;6(7):e22288.

d\. Ciccacci F, Tolno VT, Doro Altan A, Liotta G, Orlando S, Mancinelli S, et al. Non communicable diseases burden and risk factors in a cohort of HIV+ elderly patients in Malawi. AIDS Res Hum Retroviruses. 2019.

Response: We thank the reviewer for the suggested references. We have since updated our references with three of the four journal articles.

 

Reviewer \#3:

This is great piece of work given the attention that HIV/NCD comorbidity is receiving currently especially in countries with high HIV burden undergoing rapid epidemiological transition. The manuscript presents a clear and transparent research process with results emanating from appropriate analyses. However, the author is advised to consider making the following changes to improve manuscript readability and technical soundness.

Reviewer Comment 1: Table headings ought to be in uniform format. Table 1 and Table 2 headings appear to have inconsistent formats.

Response: We thank the reviewer for their comments. We have formatted the table headings and now have a consistent format from Table 1 to 4.

Reviewer comment 2: Table 2 column N should be described either by a footnote or by column heading to avoid confusing the reader with another N=271. Table 3 footnotes should be numbered consecutively:1,2,3 and not 2,2,3.

Response: We have updated the column labelling to consistently reflect a common "N" that is unambiguous. We have also updated the consecutive numbering of footnotes on Table 3.

Reviewer Comment 3: Could you please make the last columns for Table 2 wider in order to cover confidence intervals in one line other than two lines as is the case now? This would help your Table 2 look tidier.

Response: We oblige and have reformatted Table 2 to cover confidence intervals in one line.

Reviewer Comment 4: The sentence in line 53 could read better if you removed \"albeit\" and replaced \"comparable\" with \"comparably\".

Response: As per the reviewer's suggestion, we have removed the word "albeit" on line 53 and replaced "comparable" with "comparably" to improve its readability.'

Reviewer Comment 5: Please interpret statistically significant odds ratios in univariate analyses. Also in line number 35,\"unadjusted model\" should be changed to unadjusted analyses or univariate analyses since this is not one model perse, all variables assessed in univariate analyses represent individual univariate logistic models.

Response: Thank you for pointing this out. We have provided an interpretation of the significant odds ratios from univariate analysis and now refer to univariate analyses in line 256 - 257 as opposed to "unadjusted model".

Reviewer Comment 6: A sentence in line 37 reads \"When the model was adjusted, all prior significant associations between NCD diagnosis and increased age, unemployment status, BMI and CD4 ceased\" Consider changing this sentence to \"even though increased age, unemployment status, BMI and CD4 were associated with NCD diagnosis in unadjusted analyses, they were not significantly associated with NCD diagnosis in the multivariate, adjusted analyses\".

Response: As per the reviewer's suggestion, we have since updated the sentence in line 258 to read as follows \" Even though increased age, BMI and CD4 were associated with NCD diagnosis in unadjusted analyses, significant association with NCD diagnosis in the adjusted analyses remained only for categories of BMI 30 kg/m2 and above, and ages 45 years and above (borderline statistically significant)\".

Reviewer Comment 6 part B: The authors should also explain why variables with P\> 0.2 such as sex, alcohol use and smoking were included in the multivariate model as this is not consistent with their analysis plan in which an automated stepwise backward logistic regression approach was selected to build a multivariate model to determine predictors for NCD prevalence from independent predictors of NCDs with a p-value of 0.2 or less in univariate analyses.

Response: Apologies for the deficiency in description of our methods. Age, sex, alcohol use and smoking were considered apriori as potential confounders of the association of studied risk factors with NCD and included in the final multivariate logistic regression model. We have updated the statistical analysis section accordingly, line 118-119.

Reviewer Comment 7: The author should consider adding references to his claim in line number 89 \"Studies have \[90\] documented harmful consumption of alcohol, smoking tobacco, illicit drug use, and risky sexual behaviors \[91\] among KPs as factors that increase their risk for NCDs.\"

Response: As per the reviewer's comment, we have included three references that support the claim on documented harmful consumption of alcohol, smoking tobacco, illicit drug use, and risky sexual behaviors \[91\] among KPs as factors that increase their risk for NCDs.

Reviewer Comment 8: The author tries to contradict earlier research findings that they did not find an association between ART use and NCD prevalence in line number \[66\]. This should be avoided as the study was not designed to show association between ART use and NCD prevalence since the study enrolled no participants without exposure to ART. On the same note, the author also reports lack of association between NCD and detected viral load. In this study, at no point were viral load measurements reported. Therefore, such claims are not supported and should be removed from the manuscript.

Response: We thank the reviewer for this suggestion and have expunged the line 66 at the end of paragraph two in the discussion section. Indeed, our study did not enroll participants with no ART exposure therefore unable to make the claim of an association between ART use and NCD prevalence. We have also removed any mention of an association with viral load measurements in our study since these were not presented in this manuscript.

Reviewer Comment 9: The author should remove any references in the conclusion section of the manuscript.

Response: We have removed all references in the conclusion section.

Reviewer \#4:

The empirical analysis is competent, and the authors reference much of the relevant literature. A review on NCDs among key populations (KPs) is generally valuable, in light of concerns on the burden of NCDs among PLWH in general and specifically of the role and specific needs of key populations.

My reservations on publication of the paper in its present form primarily regard two aspects:

First, does the paper provide an analysis on NCDs among KPS? Not really. 94 percent of the sample are FSWs, and only 6 percent (n=86) MSMs. 86 percent of the cases of NCDs (total NCDs: n=271) are instances of high blood pressure (n=233), and the number instances of chronic respiratory disease (n=16) or cancers (n=10) do not allow a substantial empirical analysis. Against these numbers, is puzzling why much of the paper is cast in terms of \"NCDs\" among KPs -- it really is about high blood pressure among FSWs, and -- because implications and determinants of NCDs arguably differ -- focusing the empirical analysis on instances of any NCD blurs the lessons which could be learned.

Response: Thank you for the thoughtful comment. We utilized data from a routine HIV prevention and treatment program serving the two key populations. As such, the distribution of attended population and outcomes of interest was analyzed as-is. The reviewers rightly points out this and as part of the paper we now acknowledge this limitation in the discussion and have reframed our interpretation in this light. Although the paper highlights the prevalence of key NCDs in group of female and male sex workers enrolled in a funded HIV prevention and treatment program in Nairobi Kenya, majority of those with conditions of interests were women. Sex work and same sex relationships are still illegal and stigmatized in Kenya. However, females who sell sex seem to be more tolerated than MSM engaged in the trade. The latter suffer double stigma and their position is even worsened by being HIV infected. Therefore, females were over represented in the study sample as fewer men out of the many closeted MSM have taken that leap of faith to enroll in the ongoing HIV prevention and treatment programs. We acknowledge that the over representation of women in the sample limits the generalizability of results to key populations experiences in Kenya or the region. However, the data provides some insights into NCD burden in this marginalized population that has not been reported elsewhere.

Second, are there any useful findings? Note sure -- the results broadly mirror the empirical evidence on risk factors for hypertension -- prevalence is increasing with age and with BMI. Other factors appear irrelevant (this could be tested more explicitly -- do factors pervasive with respect to key populations play any role?). However, we would also want to understand whether prevalence of NCDs differs from prevalence in the general population. Doing such a comparison explicitly is beyond the scope of this paper (sample on KPs only), but the authors do not exhaust possibilities on comparing their findings with data on the general population (e.g., from DHS and related data). Relatedly, what is the relevance of the findings with regard to the management of HIV or NCDs among key populations?

Response: Again, we greatly appreciate this insightful comment. While we do acknowledge the limitations of our study in this regard, we note that our recommendation to funders and policy makers to promote integration of NCD- HIV programming in the future is evidence based too. We have previously published NCD prevalence's from the general population using similar routine HIV prevention and treatment data (ref Achwoka D, Waruru A, Chen T-H, Masamaro K, Ngugi E, Kimani M, et al. Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003-2013. 2019;19(1):372. doi: 10.1186/s12889-019-6716-2.). PLHIV in Kenya were found to have a high prevalence of NCD diagnoses with proportion of any documented NCD among PLHIV being 11.5% (95% confidence interval \[CI\] 9.3, 14.1).

Minor points:

It is not clear on what basis variables have been excluded in the multivariate analysis (Table 4). Excluding ART regimen and prior TB history appears sensible (p-value\>0.9 in univariate regression), but there are numerous other variables with p-values in the vicinity or 0.7 or 0.8 in the multivariate analysis which are included in the regression.

Response: Apologies for the deficiency in description of our methods. Age, sex, alcohol use and smoking were considered apriori as potential confounders of the association of studied risk factors with NCD and included in the final multivariate logistic regression model. We have updated the statistical analysis section accordingly.

Table 4: Review p-value of 1.11, BMI 30+ adjusted odds ratio.

Response: This was an error. The correct p-value is 0.029.

In a couple of places, I felt that the paper would benefit from a round of copy-editing to improve precision.

Response: We have revised the whole manuscript following PLOS One guideline and making the presentation as succinct as possible. The revised manuscript has a couple edits to that effect.

###### 

Submitted filename: Response to Reviewers_04_24_2020.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0235606.r003

Decision Letter 1

Francis

Joel Msafiri

Academic Editor

© 2020 Joel Msafiri Francis

2020

Joel Msafiri Francis

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

27 May 2020

PONE-D-19-32681R1

High prevalence of noncommunicable diseases among Key populations enrolled at a large HIV prevention and treatment program in Kenya
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Dear Dr. Achwoka,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 11 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Joel Msafiri Francis, MD, MS, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#4: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Many thanks for your revision. I found a great improvement with the revised version. To move on further process, I am suggesting for a few more minor revisions as described below;

1- I think you should remove capital letter of "Key populations" in the title and a few other places in the manuscript

2- I think you should add in text citation and reference for first sentence in the second paragraph (line 51-53).

3- I think you should use less human possessive term in the manuscript. You should make the language use to more academic. You should consider removing those words such as in line 72 "we only...", line 107 "Our analyses", line 136 "We analyzed", line 216 "Our proxy", line 270 "our study", line 271 "In our study", line 274 "ours among", line 286, line 289, "in our study", line 295 "we..." ... "our"... please check for the rest and you may use term "this study" to replace "our study"...

4- Do you have any rational why age, gender, alcohol use and smoking were considered as priori as potential confounder? Any learning from other literature?

5- In line 274, you mention "studies similar to ours among..." it seems does not fully completed yet.

6- At the end of the data collection or the starting of data analysis, you may add another sentence indicating that data is cleaned and imported into Stata for data analysis.

7- In the data analysis, you may need to also describe how will you report the result of of the analysis such mean, median, SD, 95% CI... and abbreviate any possible term here than you don't have to write full word in the result (eg. in line 160, 95% confident interval (CI)).

8- In line 136-138, I think this seem reported the data collection and analysis section. You may start directly reporting the result of analysis to be concise.

9- In line 139, I think you can use abbreviation of FSWs and MSM as they been abbreviated already in the introduction. You may also need to check other line to make it consistent.

10- Could you please add concrete list of inclusion / exclusion criteria for administer abstracted data? I found pieces of information from line 85 to 90 but not so convinced yet.

11- I still would like to suggest, the author consider to discuss their finding with the other studies such as "High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia" and/or "Non-communicable diseases and related risk behaviors among men and women living with HIV in Cambodia: Findings from a cross-sectional study" because I found this study is quite similar in some setting this study participant are people living with HIV even it focus to key population.

Reviewer \#2: The authors considered and addressed all the comments. The concerns related to the availability of data have been clarified.

Reviewer \#4: The authors provide competent and diligent responses to reviewers\' comments, specifically those by myself but also (according to a cursory overview) those from other reviewers.

One - I believe - important shortcoming remains. The authors do not provide a substantial discussion comparing NCDs among key populations (KPs) with the prevalence of NCDs in the general population or among PLWH overall. Understanding these differences, though, would be important for interpreting the findings and drawing policy-relevant conclusions. Are there factors specific to KPs driving high prevalence of NCDs? The findings suggest that this may not be the case, as pointers for risk behaviour come out largely insignificant (the statistically significant variables are age and BMI 30+). A pointer to the findings of the paper referred to in the response to comments (Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis\...), with some author overlap with the present paper, would also contribute to placing the findings of the present paper in context, and I find it puzzling to see that the authors do not make such connections.

This shortcoming may not preclude publication, as the analysis per se is competent, but the value of the paper is clearly diminished by the authors\' reluctance to place their findings in this wider population or PLWH context.

On the editorial side, I sense that while the language is clear throughout, the paper would benefit from one round of professional copy-editing.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Pheak Chhoun

Reviewer \#2: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235606.r004

Author response to Decision Letter 1

30 May 2020

Response to Reviewers\' Comments:

Reviewer \#1:

Many thanks for your revision. I found a great improvement with the revised version. To move on further process, I am suggesting for a few more minor revisions as described below;

1- I think you should remove capital letter of "Key populations" in the title and a few other places in the manuscript

Response: We thank the reviewer for this suggestion. We have since removed the capital letter 'K' in key populations both in the title and in the manuscript text.

2- I think you should add in text citation and reference for first sentence in the second paragraph (line 51-53).

Response: As suggested by the reviewer, we have included an in-text citation and reference for the first sentence in the second paragraph.

3- I think you should use less human possessive term in the manuscript. You should make the language use to more academic. You should consider removing those words such as in line 72 "we only...", line 107 "Our analyses", line 136 "We analyzed", line 216 "Our proxy", line 270 "our study", line 271 "In our study", line 274 "ours among", line 286, line 289, "in our study", line 295 "we..." ... "our"... please check for the rest and you may use term "this study" to replace "our study"...

Response: We continue to thank the reviewer for this important comment. The entire manuscript has been updated accordingly to rid it of human possessive terms and is now entirely in academic language.

4- Do you have any rational why age, gender, alcohol use and smoking were considered as priori as potential confounder? Any learning from other literature?

Response: We thank the reviewer for this query. The aforementioned factors met the criteria for confounding (being associated with both the risk factor of interest and the outcome, unequal distribution among comparison groups, and not being an intermediary step in causal pathway). We found these factors in our literature review and point the reviewer to the Kenya STEPwise survey for non-communicable risk factors 2015 Report.

5- In line 274, you mention "studies similar to ours among..." it seems does not fully completed yet.

Response: We realize that line 274 was unclear and have revised line 273-275 to improve clarity. It now reads " Despite a heightened impetus to refocus on populations at increased risk for both NCDs and HIV infection , studies among key populations living with HIV remain rare \[22\]. That notwithstanding, systematic reviews outside SSA suggest that sexual minorities exhibit higher rates of NCDs \[11\]".

6- At the end of the data collection or the starting of data analysis, you may add another sentence indicating that data is cleaned and imported into Stata for data analysis.

Response: We have incorporated this important suggestion in the manuscript under the sub-title 'Study procedures and data collection'. It now reads "Data were cleaned and subsequently imported to STATA 15 (STATA Corporation, Texas USA) for data analysis".

7- In the data analysis, you may need to also describe how will you report the result of of the analysis such mean, median, SD, 95% CI... and abbreviate any possible term here than you don't have to write full word in the result (eg. in line 160, 95% confident interval (CI)).

Response: We thank the reviewer for this comment. We have now included a sentence within the statistical analyses to describe reporting of analyses such as mean, SD and 95% confidence intervals.

8- In line 136-138, I think this seem reported the data collection and analysis section. You may start directly reporting the result of analysis to be concise.

Response: We agree with the reviewer's suggestion. We have since revised the lines 136-138 to avoid repetition with the data collection and analysis section. It is now concise.

9- In line 139, I think you can use abbreviation of FSWs and MSM as they been abbreviated already in the introduction. You may also need to check other line to make it consistent.

Response: We have updated the entire manuscript and checked for consistency as per the reviewer's comment. Now the abbreviations of FSWs and MSM appear consistently.

10- Could you please add concrete list of inclusion / exclusion criteria for administer abstracted data? I found pieces of information from line 85 to 90 but not so convinced yet.

Response: We have bolstered this section as suggested by the reviewer and included both inclusion and exclusion criteria for the data abstraction. As part of inclusion we considered: a) age 15 and above; b) Enrollment into the SWOP clinics between periods October 2012 and September 2015; c) HIV positive at enrollment or seroconverted during the period of study and d) Identified as MSM or FSW as typology. For exclusion we considered: a) HIV negative key population; b) other key population typology -- including PWIDs and transgender; c) key population enrolled outside the study period and d) key population under the age of 15 or missing information on age.

11- I still would like to suggest, the author consider to discuss their finding with the other studies such as "High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia" and/or "Non-communicable diseases and related risk behaviors among men and women living with HIV in Cambodia: Findings from a cross-sectional study" because I found this study is quite similar in some setting this study participant are people living with HIV even it focus to key population.

Response: We thank the reviewer for this insightful suggestion. We note that we have taken due diligence and studied the two papers. We are happy to report that the findings from the two papers from Cambodia add value to our manuscript and have been included as part of our discussion. Specifically, they are referenced in the second paragraph in the discussion.

Reviewer \#4:

Minor revisions to be made:

Reviewer Comment 1. The authors provide competent and diligent responses to reviewers\' comments, specifically those by myself but also (according to a cursory overview) those from other reviewers.

One - I believe - important shortcoming remains. The authors do not provide a substantial discussion comparing NCDs among key populations (KPs) with the prevalence of NCDs in the general population or among PLWH overall. Understanding these differences, though, would be important for interpreting the findings and drawing policy-relevant conclusions. Are there factors specific to KPs driving high prevalence of NCDs? The findings suggest that this may not be the case, as pointers for risk behaviour come out largely insignificant (the statistically significant variables are age and BMI 30+). A pointer to the findings of the paper referred to in the response to comments (Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis\...), with some author overlap with the present paper, would also contribute to placing the findings of the present paper in context, and I find it puzzling to see that the authors do not make such connections.

This shortcoming may not preclude publication, as the analysis per se is competent, but the value of the paper is clearly diminished by the authors\' reluctance to place their findings in this wider population or PLWH context.

Response: We are thankful to the reviewer for raising this important concern. We acknowledge the gravity of the reviewer's sentiments and have bolstered our discussion substantially to include comparisons of NCDs between key populations and general population PLHIV. We have included a new paragraph in the discussion section (now appears as the second paragraph) and added three references. These references include studies from concentrated HIV epidemics in Cambodia, recent modeling of NCD burden among PLHIV and general population as well as our very own study among general population PLHIV. We believe this will offer justice and improve the relevance of our study for policy conclusions.

Reviewer Comment 2. On the editorial side, I sense that while the language is clear throughout, the paper would benefit from one round of professional copy-editing.

Response: We thank the reviewer for this suggestion. We have conducted additional copy editing and would like to assure both the reviewer and editor that we now have a high-quality product commensurate to PLOS one's standards.

###### 
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###### 

Click here for additional data file.
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19 Jun 2020

High prevalence of non-communicable diseases among key populations enrolled at a large HIV prevention and treatment program in Kenya

PONE-D-19-32681R2

Dear Dr. Achwoka,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Joel Msafiri Francis, MD, MS, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#4: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I would like to thank the authors for considering the comments and revised the entires manuscript according. I have any specific comment to the manuscript in this round. Well done and should be off for the hard work.

Reviewer \#2: (No Response)

Reviewer \#4: The draft now reads much better, thanks also to the very thorough and specific comments from reviewer \#1, and is fit to see the light of day.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#4: No
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High prevalence of non-communicable diseases among key populations enrolled at a large HIV prevention & treatment program in Kenya

Dear Dr. Achwoka:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Joel Msafiri Francis

Academic Editor

PLOS ONE
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